Literature DB >> 20480271

Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 1.

Jolyon P Mitchell1, Mark W Nagel, Cathy C Doyle, Rubina S Ali, Valentina I Avvakoumova, J David Christopher, Jorge Quiroz, Helen Strickland, Terrence Tougas, Svetlana Lyapustina.   

Abstract

The purpose of this study was to compare relative precision of two different abbreviated impactor measurement (AIM) systems and a traditional multi-stage cascade impactor (CI). The experimental design was chosen to provide separate estimates of variability for each impactor type. Full-resolution CIs are useful for characterizing the aerosol aerodynamic particle size distribution of orally inhaled products during development but are too cumbersome, time-consuming, and resource-intensive for other applications, such as routine quality control (QC). This article presents a proof-of-concept experiment, where two AIM systems configured to provide metrics pertinent to QC (QC-system) and human respiratory tract (HRT-system) were evaluated using a hydrofluoroalkane-albuterol pressurized metered dose inhaler. The Andersen eight-stage CI (ACI) served as the benchmark apparatus. The statistical design allowed estimation of precision with each CI configuration. Apart from one source of systematic error affecting extra-fine particle fraction from the HRT-system, no other bias was detected with either abbreviated system. The observed bias was shown to be caused by particle bounce following the displacement of surfactant by the shear force of the airflow diverging above the collection plate of the second impaction stage. A procedure was subsequently developed that eliminated this source of error, as described in the second article of this series (submitted to AAPS PharmSciTech). Measurements obtained with both abbreviated impactors were very similar in precision to the ACI for all measures of in vitro performance evaluated. Such abbreviated impactors can therefore be substituted for the ACI in certain situations, such as inhaler QC or add-on device testing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20480271      PMCID: PMC2902354          DOI: 10.1208/s12249-010-9452-6

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  8 in total

1.  The role of inertial particle collectors in evaluating pharmaceutical aerosol delivery systems.

Authors:  V A Marple; B A Olson; N C Miller
Journal:  J Aerosol Med       Date:  1998

2.  Considerations for the development and practice of cascade impaction testing, including a mass balance failure investigation tree.

Authors:  Dave Christopher; Paul Curry; Bill Doub; Kenneth Furnkranz; Martin Lavery; Karl Lin; Svetlana Lyapustina; Jolyon Mitchell; Brian Rogers; Helen Strickland; Terrence Tougas; Yi Tsong; Bruce Wyka
Journal:  J Aerosol Med       Date:  2003

Review 3.  Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations.

Authors:  Jolyon P Mitchell; Mark W Nagel
Journal:  J Aerosol Med       Date:  2003

4.  The abbreviated impactor measurement (AIM) concept: part 1--Influence of particle bounce and re-entrainment-evaluation with a "dry" pressurized metered dose inhaler (pMDI)-based formulation.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-12       Impact factor: 3.246

5.  The abbreviated impactor measurement (AIM) concept: part II--Influence of evaporation of a volatile component-evaluation with a "droplet-producing" pressurized metered dose inhaler (pMDI)-based formulation containing ethanol as cosolvent.

Authors:  J P Mitchell; M W Nagel; V Avvakoumova; H MacKay; R Ali
Journal:  AAPS PharmSciTech       Date:  2009-03-17       Impact factor: 3.246

Review 6.  Minimizing variability of cascade impaction measurements in inhalers and nebulizers.

Authors:  Matthew Bonam; David Christopher; David Cipolla; Brent Donovan; David Goodwin; Susan Holmes; Svetlana Lyapustina; Jolyon Mitchell; Steve Nichols; Gunilla Pettersson; Chris Quale; Nagaraja Rao; Dilraj Singh; Terrence Tougas; Mike Van Oort; Bernd Walther; Bruce Wyka
Journal:  AAPS PharmSciTech       Date:  2008-02-28       Impact factor: 3.246

7.  Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs).

Authors:  Terrence P Tougas; David Christopher; Jolyon P Mitchell; Helen Strickland; Bruce Wyka; Mike Van Oort; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2009-10-29       Impact factor: 3.246

Review 8.  Canadian Standards Association standard CAN/CSA/Z264.1-02:2002: a new voluntary standard for spacers and holding chambers used with pressurized metered-dose inhalers.

Authors:  Myrna B Dolovich; Jolyon P Mitchell
Journal:  Can Respir J       Date:  2004-10       Impact factor: 2.409

  8 in total
  6 in total

1.  Measurement of drug in small particles from aqueous nasal sprays by Andersen Cascade Impactor.

Authors:  William H Doub; Wallace P Adams; Anna M Wokovich; John C Black; Meiyu Shen; Lucinda F Buhse
Journal:  Pharm Res       Date:  2012-07-03       Impact factor: 4.200

2.  Relative precision of inhaler aerodynamic particle size distribution (APSD) metrics by full resolution and abbreviated andersen cascade impactors (ACIs): part 2--investigation of bias in extra-fine mass fraction with AIM-HRT impactor.

Authors:  Jolyon P Mitchell; Mark W Nagel; Cathy C Doyle; Rubina S Ali; Valentina I Avvakoumova; J David Christopher; Jorge Quiroz; Helen Strickland; Terrence Tougas; Svetlana Lyapustina
Journal:  AAPS PharmSciTech       Date:  2010-07-10       Impact factor: 3.246

3.  Evaluation of an abbreviated impactor for fine particle fraction (FPF) determination of metered dose inhalers (MDI).

Authors:  Changning Guo; Diem Ngo; Shafiq Ahadi; William H Doub
Journal:  AAPS PharmSciTech       Date:  2013-06-19       Impact factor: 3.246

4.  Product lifecycle approach to cascade impaction measurements.

Authors:  Terrence P Tougas; Dave Christopher; Jolyon Mitchell; Svetlana Lyapustina; Michiel Van Oort; Richard Bauer; Volker Glaab
Journal:  AAPS PharmSciTech       Date:  2011-02-01       Impact factor: 3.246

5.  Good Cascade Impactor Practice (GCIP) and considerations for "in-use" specifications.

Authors:  S C Nichols; J P Mitchell; C M Shelton; D L Roberts
Journal:  AAPS PharmSciTech       Date:  2013-01-24       Impact factor: 3.246

6.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.